chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A few days prior to 11/02/2022, I would have episodes that I would get lightheaded. Occasionally, I would get up in the morning, the room would spin a little bit. On 11/02/2022, I had a full episode of vertigo, where the room was spinning around. I was shopping, and I turned around and the spinning hit me suddenly. I was holding on to my grocery cart and I got to a point where I could sit for 10 minutes and felt better. I went to the ENT on 11/03/2022. They did a hearing test and said my hearing was fine. I still have lightheadedness. I have to do a vertigo exercise every day. Prior to the COVID-19 vaccines, I never had vertigo.
V received both the flu and pneumonia vaccines on 10/3.  She received the pneumonia vaccine in the right arm.  Later that night, she began experiencing headaches, body aches, and nasal congestion.  The patients daughter stated that her eyes are red and her right arm is red and swollen.
This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 55-year-old female patient who received Herpes zoster (shingrix) for prophylaxis. Previously administered products included shingrix (1st dose received on 26th April 2021, batch number NE49X, expiry date 23rd August 2022). On an unknown date, the patient received the 2nd dose of shingrix. On an unknown date, unknown after receiving shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown. Additional details were provided as follows: The age at vaccination was not applicable for this report. The patient was a part of the GSK (GlaxoSmithKline) assistance program and received first dose of shingrix through the program. The Pharmacy has had an issue getting the second dose through the program, so the patient had not yet received the second dose, which led to incomplete course of vaccination. The reporter consented to follow up.
pt recv vax 30JUL96 & it was unk which arm recv the vax;same day p/vax pt devel a mild case of varicella-vesicular lesions on trunk & thigh;pt recovered;
temperature excursion involving PROQUAD; This spontaneous report was received from a nurse refers to a patient of unknown age and gender. The patient's medical history, historical drugs, concurrent conditions and concomitant medications were not provided.     On 07-DEC-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA)(PROQUAD) 0.5 milliliter, lot number T011302 (conflicting information as it was also reported as T021302), expiration date 19-FEB-2021 (route of administration not provided) for prophylaxis.  The vaccine had a temperature excursion of -5 degrees Celsius for 20 hours. There were no previous temperature excursions. The call was due to digital data logger.  This is one of several cases reported by the same reporter.; Sender's Comments:  US-009507513-2012USA010555: US-009507513-2012USA010556: US-009507513-2012USA010579: US-009507513-2012USA010585: US-009507513-2012USA010590: US-009507513-2012USA010592: US-009507513-2012USA010629: US-009507513-2012USA010652: US-009507513-2012USA010667: US-009507513-2012USA010678: US-009507513-2012USA010686: US-009507513-2012USA010698: US-009507513-2012USA010722: US-009507513-2012USA010725: US-009507513-2012USA011227:
Pt recvd vax 17SEP92 & following vax pt devel pain down to elbow & up across chest;
No adverse effects; who received the GARDASIL 9, May 29, 2019 first dose and then October 9, 2019 second dose beyond the two month recommended schedule; This spontaneous report as received from a patient of unknown age and gender. The patient's concomitant medications, pertinent medical history and drug reactions/allergies was not provided.    On 29-MAY-2019, the patient was vaccinated with first dhpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) dose 1 (lot# expiry date, strength, route of administration and anatomical locations were unknown) for prophylaxis On 09-OCT-2019, the patient was vaccinated with first dhpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) dose 2 for prophylaxis. The second dose was received more than the two month recommended schedule (inappropriate schedule of product administration). No additional adverse effects were reported.
Rash all over the body after two days of injections which has gotten bigger. No fever and no other symptoms.
The patient was given the AFLURIA NDC: 33332-0017-02. Lot number# XT33908 on 01/20/2018 at Pharmacy. The patient came back on 01/28/2018 with a big bruise on her arm, saying that the bruise started the same day she got the vaccine but it got darker over the week with pain that doesn't seem to go away even a week after. Asked the patient if taking any prescription drugs the answer was no. Asked if the patient had a flu shot before and the answer was yes( many times) without a problem.
transverse myelitis; Initial information received on 29-Oct-2019 regarding an unsolicited valid serious case received from a consumer/Non health care professional (patient).  This case involves a 34 years old male patient who experienced transverse myelitis (Myelitis transverse), while she received vaccine INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED [FLUZONE].  The patients past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 17-Oct-2016, the patient received 0.5 ml dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED lot UI684AE and Exp. Date 30-Jun-2017 via intradermal/intramuscular (patient could not recall) route in unknown administration site.  On an unknown date, the patient developed transverse myelitis (myelitis transverse) (latency unknown) following the administration of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED. This event was assessed as medically significant.  Details of lab data were not reported.  Final diagnosis was transverse myelitis.  It was not reported if the patient received any corrective treatment.  The outcome of transverse myelitis not reported at the time of reporting.; Sender's Comments: This case concerns a 34 years old female patient who presented with transverse myelitis after vaccination with FLUZONE. The time to onset is unknown. The exact cause of transverse myelitis is unknown, however, autoimmune disorder, infection or vaccination are known factors for development of  this condition which need to be ruled out before a causal role of the vaccine can be assessed. Further information including patient's medical history, condition at the time of vaccination, immune status and lab tests excluding other etiology would be needed to fully assess this case. Based upon the reported information, the role of the vaccine cannot be assessed.
Vaccine was received on 12/31.  A rash began on 01/06 on the chest, stomach and back as well as at the injection site.  Since, rash also spread to arm and legs. Unclear from notes if patient received further escalation of care of if the rash resolved on its own.
Pt has a red, swollen area on (L) arm measuring 11 cm x 15 cm, pt describes as "itchy".
Arm swollen and hurt. States has problems with it hurting ever since went to MD and was prescribed topical steroids. He itched all over.
Patient had some swelling in the arm around where the shot was given.  It was hot to the touch.  She complained it was painful to move.  The redness and irritation started about 24 hours after vaccination.  She was advised to take Benadryl by mouth.
Had fever 105; Seen by MD who ordered blood cultures; Started on ATB; Md stated pt had rxn to pertussis;
48 hours after my first dose, "I" had chills; Tiredness; Vomited; Fever; Joint pain; Extreme lower back pain; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0150) via an unspecified route of administration in the left arm on 08Apr2021 at 11:30 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included type II diabetes and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included insulin glargine (LANTUS INSULIN) and dulaglutide (TRULICITY) both for an unknown indication from an unknown dates and unknown if ongoing. The patient previously took tetanus vaccine (MANUFACTURER UNKNOWN) and insulin lispro (HUMALOG) for an unknown indication from an unknown dates and experienced drug allergy. On 10Apr2021 at 12:00, 48 hours after her first dose, the patient experienced chills, tiredness, vomited, fever, joint pain and extreme lower back pain. The events did not result in doctor or other healthcare professional office or clinic, emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, tiredness, vomited, fever, joint pain and extreme lower back pain were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Cards reflects the wrong lot numbers and we can not figure out which patient's records are wrong.; Circumstance or information capable of leading to medication error; The patient have not reported any adverse reactions; This spontaneous case was reported by a pharmacist and describes the occurrence of TRANSCRIPTION MEDICATION ERROR (Cards reflects the wrong lot numbers and we can not figure out which patient's records are wrong.), CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Circumstance or information capable of leading to medication error) and NO ADVERSE EVENT (The patient have not reported any adverse reactions) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 09-Jan-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced TRANSCRIPTION MEDICATION ERROR (Cards reflects the wrong lot numbers and we can not figure out which patient's records are wrong.), CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Circumstance or information capable of leading to medication error) and NO ADVERSE EVENT (The patient have not reported any adverse reactions). At the time of the report, TRANSCRIPTION MEDICATION ERROR (Cards reflects the wrong lot numbers and we can not figure out which patient's records are wrong.), CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Circumstance or information capable of leading to medication error) and NO ADVERSE EVENT (The patient have not reported any adverse reactions) outcome was unknown. Not Provided      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (The patient have not reported any adverse reactions) to be not related. No further causality assessments were provided for TRANSCRIPTION MEDICATION ERROR (Cards reflects the wrong lot numbers and we can not figure out which patient's records are wrong.) and CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Circumstance or information capable of leading to medication error).    This case contains information for the 9th of 16 patients described by the reporter.  No concomitant medications were reported.  Patient received additional booster.  It has been reported that 26 patients received bivalent vaccines from 2 different Bivalent lot numbers on 09-Jan-2023 they were lot numbers: 061F22A and AS7170B. For all 26 patients' vaccine cards lot number has been written as AS7170B.  For 16 patients Vaccination Cards reflected the wrong lot numbers. Additionally, it has been reported that all patients received the correct vaccine and bivalent dose and the error only involved in documentation.  No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-696236.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-696236:Master case
pt hospitalized w/eye pain, gait instability, lethargy & disorientation 3 wks p/vax; mental status alteration & bilateral visual loss secondary to optic neuritis; dx parainfectious encephalomyelitis; MRI showed bilat involv of thalamus;
pt recv vax;pt gives hx of devel maculopapular rash on arms & legs, started 6 hr p/ vax; itching & raised bumps; seen by MD;
I received both Pfizer COVID vaccine shots (first dose on 5/11/21, second dose 6/2/21). I have not had eczema in 10+ years, and four days after getting the first dose I developed eczema again. It has now been 6 months and I still have eczema that has not improved since May despite using many different creams and seeing a dermatologist.
her allergies and itching has been worse; hives; itching; allergies; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.   An 85-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 17Oct2022 as dose number unknown (booster), single (Batch/Lot number: unknown) at the age of 84 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for COVID-19 immunization. The following information was reported: HYPERSENSITIVITY (non-serious) with onset 18Oct2022, outcome "not recovered", described as "allergies"; URTICARIA (non-serious) with onset 18Oct2022, outcome "unknown", described as "hives"; PRURITUS (non-serious) with onset 18Oct2022, outcome "not recovered", described as "itching"; CONDITION AGGRAVATED (non-serious) with onset Dec2022, outcome "not recovered", described as "her allergies and itching has been worse". Therapeutic measures were taken as a result of urticaria, pruritus, hypersensitivity.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
woke up 6hr p/taking pill @ bedtime w/intense cramping, sweats, & had 2 episodes of diarrhea;for that day & following, had milder cramping in short episodes with longer time between the episodes as time went on;
15JAN99 c/o nausea;late evening aches/pains/h/a lasted into 16JAN99;by 9PM on 16JAN99 c/o cold, chills, fever 101.7 & hurt to walk;advised by ER MD via phone to to get addtl vaccine of hep b;17JAN99 pt feeling better;pt doesn't have PCP;
This spontaneous report was received from a license practical nurse via a company representative referring to an 18 week 2 day old female patient. No information was provided regarding the patient's medical history, concurrent conditions or concomitant medications. On 29-MAY-2018, the patient was vaccinated with the first dose of ROTATEQ lot number R003534 for prophylaxis. No adverse effects were reported.
The vial was initially stored in the refrigerator on 08-Jul-2022 and vaccine was administered on 09-Aug-2022.; No Adverse Event; Vaccine administered to the patient after 30-day use by date; This spontaneous case was reported by a physician assistant and describes the occurrence of PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and vaccine was administered on 09-Aug-2022.), EXPIRED PRODUCT ADMINISTERED (Vaccine administered to the patient after 30-day use by date) and NO ADVERSE EVENT (No Adverse Event) in a 9-month-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1414B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 09-Aug-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 09-Aug-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine administered to the patient after 30-day use by date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and vaccine was administered on 09-Aug-2022.) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and vaccine was administered on 09-Aug-2022.), EXPIRED PRODUCT ADMINISTERED (Vaccine administered to the patient after 30-day use by date) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessments were provided for PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 08-Jul-2022 and vaccine was administered on 09-Aug-2022.) and EXPIRED PRODUCT ADMINISTERED (Vaccine administered to the patient after 30-day use by date).    Concomitant medications were not provided by the reporter. Reporter stated that they administered approximately 50 doses of moderna covid-19 vaccine from 5 vials after 30-day use by date. Vials were initially stored in the fridge on 8-Jul-2022. The vials did not undergo any temperature excursion. The healthcare professional was not aware of any symptoms for any patient after the vaccine was given. No treatment medications were reported.
he experienced tenderness; pain; This is a spontaneous report from a Pfizer sponsored program Support from a contactable consumer (patient). A male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number: unknown, Expiration date: unknown), via an unspecified route of administration, administered at an unspecified anatomical location on 23Feb2021 as dose 1, single for COVID-19 immunization. The patient's medical history included stent placement (He has a stent on his heart) and coronary artery disease (Patient has Coronary Artery Disease) from an unknown date and unknown if ongoing. On an unspecified date in Feb2021 the patient experienced he experienced tenderness and pain. Patient wants to know if he still need to take the second dose. The outcome of the events was unknown.  No follow-up attempts are Possible. Information on lot/batch cannot be obtained.
Left ear ache; Got first dose on 09Apr2021, did not get second dose yet; This spontaneous case was reported by a consumer and describes the occurrence of EAR PAIN (Left ear ache) and PRODUCT DOSE OMISSION ISSUE (Got first dose on 09Apr2021, did not get second dose yet) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Jun-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Got first dose on 09Apr2021, did not get second dose yet). On an unknown date, the patient experienced EAR PAIN (Left ear ache). On 04-Jun-2021, PRODUCT DOSE OMISSION ISSUE (Got first dose on 09Apr2021, did not get second dose yet) had resolved. At the time of the report, EAR PAIN (Left ear ache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided.
my arm is very bad paining; feel flushed; my all body and face go flush; Nauseous; just don't feel good; This is a spontaneous report from a contactable consumer (patient). An unspecified age and gender patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection) via an unspecified route of administration on an unspecified date as dose number unknown, single for COVID-19 immunisation. Patient medical history and concomitant medications were not reported. On an unspecified consumer stated that I had a shot yesterday and I took of Pfizer and did a COVID test and further clarification unknown. I just don't feel good and "I don't have the rash and I have the short yesterday, my arm is very bad paining in the arm, no worries it's okay I can handle it and I am Nauseous and I feel flushed too because I do exercise and my all body and face go flush. Patient stated I don't want to go the hospital, I don't want to go such places because I take Psychiatric medication (Further clarification Unknown)". Outcome of events was unknown.  Information about the Lot/batch number has been requested.
sick; dizzy; headache; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (sick), DIZZINESS (dizzy) and HEADACHE (headache) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Arthritis and Fibromyalgia. Concomitant products included DICLOFENAC SODIUM, MISOPROSTOL (ARTHROTEC) for an unknown indication.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Mar-2021, the patient experienced ILLNESS (sick), DIZZINESS (dizzy) and HEADACHE (headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 12-Mar-2021, ILLNESS (sick) and DIZZINESS (dizzy) had resolved. At the time of the report, HEADACHE (headache) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
PNEUMOVAX vaccine given 11/8/11 IM left deltoid. The night after her vaccine she was achy all over had a headache - the morning of 11/10/11 she noted 3 large whelps on left posterior upper arm - she did not come to clinic as planned. She took BENADRYL evening of 11/10/11 - by morning she noted improvement & redness & tenderness completely gone by AM 11/12/11.
Third dose was given as a booster dose, which did not meet the recommended guidelines for age. Patient does not have any qualifying immune compromising diagnoses to qualify dose as valid.
4:30 pm - "lightheaded, sore muscles and joints, burning eyes, feverish without checking temperature". Took Midol for usual menstrual cramps and back ache. 7/24/07 - Menstrual sx improved. Feels "hot and cold". Feeling better today, "hungry pain".
None known; pt was given PE 1JUL92 & no abnormal findings noted;
Patient received flu shot at 5:00 in the evening. Later that night, at about 3 AM, patient woke up experienceing vomiting, diarrhea, and stomach pain.